|
注册号: Registration number: |
ChiCTR2500107243 |
|
最近更新日期: Date of Last Refreshed on: |
2025-08-06 18:12:46 |
|
注册时间: Date of Registration: |
2025-08-06 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
胚胎植入前非整倍体遗传学检测在反复妊娠丢失患者中的临 床有效性评价:一项多中心、随机、对照临床研究 |
|
Public title: |
Live birth rate after preimplantation genetic testing for aneuploidy versus conventional in vitro fertilization among couples with recurrent pregnancy loss: A multicenter randomized controlled clinical trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
胚胎植入前非整倍体遗传学检测在反复妊娠丢失患者中的临 床有效性评价:一项多中心、随机、对照临床研究 |
|
Scientific title: |
Live birth rate after preimplantation genetic testing for aneuploidy versus conventional in vitro fertilization among couples with recurrent pregnancy loss: A multicenter randomized controlled clinical trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
孙贇 |
研究负责人: |
孙贇 |
|
Applicant: |
Yun Sun |
Study leader: |
Yun Sun |
|
申请注册联系人电话: Applicant telephone: |
+86 21 2028 4500 |
研究负责人电话:
Study leader's |
+86 21 2028 4500 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
syun163@163.com |
研究负责人电子邮件: Study leader's E-mail: |
syun163@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市浦东新区灵山路845号 |
研究负责人通讯地址: |
浦建路160号 |
|
Applicant address: |
845 Lingshan Road, Pudong New District, Shanghai |
Study leader's address: |
No.160, Pujian Road, Shanghai, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海交通大学医学院附属仁济医院 |
||
|
Applicant's institution: |
Renji Hospital, Shanghai Jiaotong University School of Medicine |
||
|
研究负责人所在单位: |
上海交通大学医学院附属仁济医院 |
||
|
Affiliation of the Leader: |
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
LY2025-192-C |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海交通大学医学院附属仁济医院研究伦理分委会C组 |
||
|
Name of the ethic committee: |
Shanghai Jiaotong University School of Medicine Renji Hospital Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-06-26 00:00:00 | ||
|
伦理委员会联系人: |
陆麒 |
||
|
Contact Name of the ethic committee: |
无 |
||
|
伦理委员会联系地址: |
浦建路160号 |
||
|
Contact Address of the ethic committee: |
No.160, Pujian Road, Shanghai, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 5875 2345 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
rjluqi@hotmail.com |
|
研究实施负责(组长)单位: |
上海交通大学医学院附属仁济医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
浦建路160号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.160, Pujian Road, Shanghai, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-raised |
||||||||||||||||||||||
|
研究疾病: |
反复妊娠丢失 |
||||||||||||||||||||||
|
Target disease: |
Recurrent pregnancy loss |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
在反复妊娠丢失患者(RPL)中,通过随机对照临床研究方法,比较应用胚胎植入前非整倍体检测技术筛选后单囊胚移植与常规基于形态学筛选后单囊胚首次移植后的妊娠结局、母儿并发症风险,探讨胚胎植入前非整倍体检测技术治疗RPL患者的有效性和安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
In this randomized trial among patients with recurrent pregnancy loss (RRL), we aim to compare the pregnancy outcomes and the risk of maternal and fetal complications after single blastocyst transfer following embryo selection with preimplantation genetic testing for aneuploidy screening versus with routine morphologic screening, and to explore the effectiveness and safety of preimplantation genetic testing for aneuploidy in treatment for RRL. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1)明确的影响宫腔形态或内膜容受性疾病,如未经治疗的子宫畸形(纵膈子宫、单角子宫、双子宫等)、粘膜下肌瘤、输卵管积水等 2)拟行胚胎植入前染色体结构异常检测(PGT-SR)或胚胎植入前单基因检测(PGT-M) 3)使用供精或供卵助孕 4)有妊娠和/或辅助生殖技术禁忌症; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus unicornate, bicornate, or duplex); untreated uterine septum, submucous myoma, multiple endometrial polyp(s); or with untreated hydrosalpinx; 2. Women who are indicated and planned to undergo PGT-M or PGT-SR; 3. Women who use donated oocytes or sperm to achieve pregnancy; 4. Women with medical contraindications to assisted reproductive technology and/or pregnancy. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-07-01 00:00:00至 To 2029-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-08-06 00:00:00 至 To 2028-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
将在714例RPL患者中,在胚胎培养D5天或D6天,按照1:1的比例随机分为两组。采用区组随机方法,数据协调中心将利用SAS软件生成随机分组数字表。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
On day 5 or day 6 of embryo culture, 714 RPL patients will be randomized into two groups by 1:1 ratio. Blocked randomization will be used. Data coordinator center will generate random number sequence by SAS software. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
开放标签 |
|
Blinding: |
Open-label study |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束2年后 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
2 years after completion of the trial. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
我们将同时采用CRF表和电子系统收集管理数据,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
We will use Case Record Form and Electronic Data Capture platform for data collection and management. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |